Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications

Francisco Espinoza, Sylvie Fabre, Yves Marie Pers*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


Recent guidelines on rheumatoid arthritis (RA) point to the importance of achieving remission as soon as possible during the course of the disease. The appropriate use of antirheumatic drugs is critical, particularly in early RA patients, before 24 weeks, since this is a ‘window of opportunity’ for treatment to modify disease progression. A treat-to-target strategy added to an aggressive therapeutic approach increases the chance of early remission, particularly in early RA patients. We conducted an overview of current therapeutic strategies leading to remission in early RA patients. We also provide interesting predictive factors that can guide the RA management strategy with regard to disease-modifying treatment and/or drug-free remission.

Original languageEnglish
Pages (from-to)107-118
Number of pages12
JournalTherapeutic Advances in Musculoskeletal Disease
Issue number4
StatePublished - 1 Aug 2016

Bibliographical note

Publisher Copyright:
© The Author(s), 2016.


  • disease-modifying antirheumatic drugs
  • early rheumatoid arthritis
  • predictive factors
  • remission
  • rheumatoid arthritis


Dive into the research topics of 'Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications'. Together they form a unique fingerprint.

Cite this